Anika Commences U.S. Commercial Launch of TACTOSET Bone Repair Therapy Under Its New U.S. Hybrid Commercial Model
Anika Therapeutics, Inc., a global, integrated orthopedic medicines company leveraging its proprietary hyaluronic acid technology platform to provide therapies across the Joint Preservation and Restoration continuum of care, today announced it has commenced the U.S. commercial soft launch of TACTOSET, its injectable HA-enhanced bone repair therapy. TACTOSET has been developed for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. TACTOSET is Anika’s first product to launch under its U.S.-based hybrid commercial model.
“We are proud to commence the launch of our first surgically-delivered regenerative therapy in the U.S. under our hybrid commercial model with the addition of TACTOSET to our product portfolio,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “We believe our hybrid commercial model provides us with a direct line of sight into the market, enabling Anika to achieve rapid market penetration with TACTOSET, while avoiding the significant investment associated with building a large direct sales force internally. Additionally, we expect our hybrid model to provide the ability to launch in various phases and to scale where appropriate as we introduce products across multiple categories in the Orthopedic segment. This capability gives our commercial team more precise commercial control, including greater visibility on product demand, end-user activity and fulfillment.”
Approximately 900,000 people could benefit from treatment for bone voids and other bone defects of the skeletal system, which can cause pain and impaired function. This therapy combines calcium phosphate, an established precursor to the mineral component of bone, with Anika’s proprietary hyaluronic acid, which enhances flow and tactile feel during administration, to improve ease of use and procedural efficiency.
“I am very pleased with my TACTOSET surgical experience, due in large part to its unique ease-of-use,” said Dr. John Tierney, President of the Greater Boston Orthopaedic Center, and the first surgeon to utilize the product in a human case. “I believe that other patients and surgeons in the field will realize the benefits of the product, and I look forward to discussing my clinical experience during Anika’s Analyst and Investor Day later this morning.”
Anika will discuss the benefits of this novel therapy and the value of its hybrid commercial strategy at the Company’s Analyst and Investor Day being held today, September 18, 2019.
